Dry and Wet Age-Related Macular Degeneration – Landscape & Forecast – Disease Landscape & Forecast

Age-related macular degeneration (AMD) is a degenerative and progressive ocular disease that diminishes central visual acuity as a result of photoreceptor degeneration in the macula. The wet AMD market has long been dominated by three anti-vascular endothelial growth factors (VEGFs), including Roche / Genentech / Chugai’s off-label compounded Avastin, Roche / Genentech / Novartis’s Lucentis, and Regeneron / Bayer HealthCare / Santen’s Eylea. We expect newer entrants to the market, Roche / Chugai’s Vabysmo (faricimab) and Regeneron / Bayer’s Eylea HD to continue to experience strong uptake, driven mostly by their advantageous dosing regimen. Competition will increase in the wet AMD market with the launch of emerging therapies including aflibercept biosimilars and Regenxbio / AbbVie’s ABBV-RGX-314, promising lower cost and longer dosing intervals, respectively. By contrast, the management of geographic atrophy (GA) is limited to Apellis’s Syfovre and Astellas’s Izervay, which launched in the United States in 2023.

Questions answered

  • How will the wet AMD treatment algorithm change as new products launch? To what extent will they capitalize on the need for therapies with longer dosing intervals?
  • How will market dynamics be impacted by the launch of biosimilars of Eylea?
  • How receptive are retinal specialists to novel gene therapy approaches and to emerging therapies for wet AMD and GA?
  • What is U.S. retinal specialists’ first impression of the first treatments for GA?
  • What improvements would late-phase wet AMD therapies need to demonstrate to compete effectively in an increasingly fragmented market?

Content highlights

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 29 country-specific interviews with thought-leading retinal specialists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Total prevalence of late AMD, by country, segmented by GA and wet AMD subpopulations, including diagnosed and drug-treated rates.

Forecast: 10-year, annualized, drug-level sales and patient share of key GA and wet AMD therapies through 2032, segmented by brands / biosimilars and epidemiological subpopulations.

Emerging therapies: Phase 3 / PR: 7 drugs; Phase 2: 17 drugs; coverage of select Phase 1 products.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

launch Related Market Assessment Reports